Thiogenesis Therapeutics Corp.
Thiogenesis Therapeutics, Corp., a clinical-stage biopharmaceutical company, develops thiol-based therapeutic compounds to treat unmet pediatric medical needs. Its lead product candidate is TTI-0102, a prodrug that consists of cysteamine for use in the treatment of mitochondrial encephalopathy lactic acidosis and stroke-like episodes, leigh syndrome, pediatric metabolic dysfunction-associated ste… Read more
Thiogenesis Therapeutics Corp. (TTI) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.986x
Based on the latest financial reports, Thiogenesis Therapeutics Corp. (TTI) has a cash flow conversion efficiency ratio of -0.986x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-2.12 Million) by net assets (CA$2.15 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Thiogenesis Therapeutics Corp. - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Thiogenesis Therapeutics Corp.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Thiogenesis Therapeutics Corp. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Thiogenesis Therapeutics Corp. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ACCESS Newswire Inc.
NYSE MKT:ACCS
|
-0.019x |
|
KWANGJIN WINTEC CO. Ltd
KQ:090150
|
0.040x |
|
Pamel Yenilenebilir Elektrik Uretim AS
IS:PAMEL
|
-0.009x |
|
Canfor Pulp Products Inc
PINK:CFPUF
|
-0.059x |
|
Nectar Lifesciences Limited
NSE:NECLIFE
|
0.213x |
|
Samhwa Networks Co. Ltd
KQ:046390
|
0.086x |
|
Kocom Co. Ltd
KQ:015710
|
0.036x |
|
Bakrie & Brothers Tbk
JK:BNBR
|
-0.086x |
Annual Cash Flow Conversion Efficiency for Thiogenesis Therapeutics Corp. (2019–2024)
The table below shows the annual cash flow conversion efficiency of Thiogenesis Therapeutics Corp. from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CA$3.43 Million | CA$-3.92 Million | -1.145x | -94.84% |
| 2023-12-31 | CA$5.53 Million | CA$-3.25 Million | -0.587x | -68.19% |
| 2022-12-31 | CA$5.98 Million | CA$-2.09 Million | -0.349x | -131.80% |
| 2021-12-31 | CA$-61.07K | CA$-67.08K | 1.098x | +355.18% |
| 2020-12-31 | CA$83.35K | CA$-35.88K | -0.430x | +39.55% |
| 2019-12-31 | CA$280.27K | CA$-199.58K | -0.712x | -- |